NF-κB dysregulation in multiple myeloma

Semin Cancer Biol. 2016 Aug:39:68-76. doi: 10.1016/j.semcancer.2016.08.005. Epub 2016 Aug 17.

Abstract

The nuclear factor-κB (NF-κB) transcription factor family plays critical roles in the pathophysiology of hematologic neoplasias, including multiple myeloma. The current review examines the roles that this transcription factor system plays in multiple myeloma cells and the nonmalignant accessory cells of the local microenvironment; as well as the evidence indicating that a large proportion of myeloma patients harbor genomic lesions which perturb diverse genes regulating the activity of NF-κB. This article also discusses the therapeutic targeting of the NF-κB pathway using proteasome inhibitors, a pharmacological class that has become a cornerstone in the therapeutic management of myeloma; and reviews some of the future challenges and opportunities for NF-κB-related research in myeloma.

Keywords: Microenvironment; Myeloma; NF-kappaB; Proteasome inhibitors; Stromal cells.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Humans
  • Molecular Targeted Therapy / methods
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / genetics
  • Multiple Myeloma / metabolism*
  • NF-kappa B / genetics*
  • NF-kappa B / metabolism*
  • Signal Transduction
  • Tumor Microenvironment

Substances

  • NF-kappa B